医学
乳腺癌
增殖标记
Ki-67
免疫组织化学
肿瘤科
癌症
化疗
内科学
代理终结点
病理
作者
Ander Urruticoechea,Ian E. Smith,Mitch Dowsett
标识
DOI:10.1200/jco.2005.07.501
摘要
Molecular markers have been extensively investigated with a view to providing early and accurate information on long-term outcome and prediction of response to treatment of early breast cancer. Proliferation is a key feature of the progression of tumors and is now widely estimated by the immunohistochemical assessment of the nuclear antigen Ki-67. The expression of Ki-67 correlates with other measurements of proliferation, including S-phase and bromodeoxyuridine uptake. High Ki-67 is a sign of poor prognosis associated with a good chance of clinical response to chemotherapy, but its independent significance is modest and does not merit measurements in most routine clinical scenarios. However, its application as a pharmacodynamic intermediate marker of the effectiveness of medical therapy holds great promise for rapid evaluation of new drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI